Product Information
LAMIVUDINE-ZIDOVUDINE TABLET is a generic product labeled by Camber Pharmaceuticals Inc., priced at $0.7707 per EA under NDC 31722050660. Its NADAC has been published 530 times since Aug 10, 2016.
FDA first approved this application on Sep 17, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150; 300 mg/1; mg/1
Manufacturer
Camber Pharmaceuticals Inc.NDC
31722050660
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LAMIVUDINE; ZIDOVUDINEApproval Type
Generic (ANDA)
FDA Application
ANDA079124FDA Approved
9/17/2015
TE Code
AB
On Market Since
9/18/2015
Pharmacological Classes
Price Statistics
The NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has been published 530 times since Aug 10, 2016, and over the history we have for it it has declined 64.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7707 per EA |
|---|---|
| All-time high | $2.6615 (Sep 14, 2016) |
| All-time low | $0.5570 (Jan 21, 2026) |
| 52-week high | $0.7707 |
| 52-week low | $0.5570 |
| Median price | $0.9217 |
| Average price | $1.0217 |
| Largest weekly change | +57.7% (Aug 21, 2019) |
| Weeks tracked | 530 |
| Tracking since | Aug 10, 2016 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the LAMIVUDINE and ZIDOVUDINE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Camber Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
LAMIVUDINE and ZIDOVUDINE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of LAMIVUDINE-ZIDOVUDINE TABLET?
The current National Average Drug Acquisition Cost (NADAC) for LAMIVUDINE-ZIDOVUDINE TABLET, manufactured by Camber Pharmaceuticals Inc., is $0.7707 per EA (NDC 31722050660), effective Sep 30, 2026.
How has the price of LAMIVUDINE-ZIDOVUDINE TABLET changed over time?
Over the history we have for it, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has declined 64.6%. It has been tracked across 530 weekly CMS publications since Aug 10, 2016.
What are the highest and lowest recorded NADAC prices for LAMIVUDINE-ZIDOVUDINE TABLET?
Since Aug 10, 2016, the NADAC for LAMIVUDINE-ZIDOVUDINE TABLET has ranged from a low of $0.5570 (Jan 21, 2026) to a high of $2.6615 (Sep 14, 2016), with a median of $0.9217 per EA.
Are there cheaper alternatives to LAMIVUDINE-ZIDOVUDINE TABLET?
No other NADAC-published product currently shares the active ingredient and strength of LAMIVUDINE-ZIDOVUDINE TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures LAMIVUDINE-ZIDOVUDINE TABLET?
LAMIVUDINE-ZIDOVUDINE TABLET (NDC 31722050660) is labeled by Camber Pharmaceuticals Inc., and CMS classifies it as a generic product.